To print: Select File and then Print from your browser's menu

Title: Patanol(R) (Olopatadine Hydrochloride Ophthalmic Solution), Approved in Japan for Allergic Conjunctivitis

"Patanol(R) (Olopatadine Hydrochloride Ophthalmic Solution), Approved in Japan for Allergic Conjunctivitis"

FORT WORTH, TX -- July 27, 2006 -- Alcon, Inc. announced that it has received approval from the Ministry of Health, Labor and Welfare in Japan to market its eye allergy drug, Patanol® (olopatadine hydrochloride ophthalmic solution) 0.1%, for allergic conjunctivitis. Patanol(R) solution provides both mast cell stabilizing and anti-histamine properties in a single molecule, providing patients with rapid, effective and lasting relief from the signs and symptoms of allergic conjunctivitis, an allergen-induced inflammatory response characterized by ocular itching, redness and tearing. Japan is the world's second largest ocular allergy market and therefore represents a significant business opportunity for the company to expand sales of Patanol® solution, according to Alcon Japan President Scott Manning. "The approval of Patanol® solution is an important development for Alcon," said Manning. "We anticipate launching this product in Japan this year and will be expanding our sales force to maximize this opportunity. We expect Patanol® solution to be a contributor to our future growth and also anticipate that this product will be adopted by the medical community and will provide optimal ocular relief and comfort to patients who suffer from eye allergies." Patanol® solution is approved in 83 countries including the United States where it has become the leading product for the treatment for ocular allergy. SOURCE: Alcon, Inc.

Copyright © 2010 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.